$81.76
+0.07
(+0.09%)▲
Medtronic PLC is a global medical device company that provides innovative solutions to improve patient outcomes and reduce healthcare costs.
Insights on Medtronic Plc
Revenue is up for the last 3 quarters, 7.70B → 8.08B (in $), with an average increase of 2.4% per quarter
Netprofit is up for the last 3 quarters, 791.0M → 1.32B (in $), with an average increase of 22.1% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.3% return, outperforming this stock by 50.6%
In the last 3 years, Boston Scientific Corp. has given 69.3% return, outperforming this stock by 105.1%
0.6%
Downside
Day's Volatility :1.46%
Upside
0.86%
17.18%
Downside
52 Weeks Volatility :23.96%
Upside
8.18%
Period | Medtronic Plc | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -6.9% | -2.2% | 3.5% |
6 Months | 11.26% | 9.8% | 17.4% |
1 Year | -9.42% | 5.4% | 24.0% |
3 Years | -35.83% | 14.3% | 22.0% |
Market Capitalization | 106.7B |
Book Value | $38.95 |
Dividend Share | 2.75 |
Dividend Yield | 3.43% |
Earnings Per Share (EPS) | 3.15 |
PE Ratio | 25.52 |
PEG Ratio | 1.52 |
Wall Street Target Price | 94.0 |
Profit Margin | 13.0% |
Operating Margin TTM | 19.17% |
Return On Assets TTM | 4.23% |
Return On Equity TTM | 8.17% |
Revenue TTM | 32.3B |
Revenue Per Share TTM | 24.3 |
Quarterly Revenue Growth YOY | 4.7% |
Gross Profit TTM | 21.7B |
EBITDA | 8.7B |
Diluted Eps TTM | 3.15 |
Quarterly Earnings Growth YOY | 0.08 |
EPS Estimate Current Year | 5.2 |
EPS Estimate Next Year | 5.45 |
EPS Estimate Current Quarter | 1.26 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 14.97%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 30.0B | ↑ 0.82% |
Net Income | 3.1B | ↓ 22.94% |
Net Profit Margin | 10.36% | ↓ 3.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 30.6B | ↑ 2.02% |
Net Income | 4.6B | ↑ 49.19% |
Net Profit Margin | 15.16% | ↑ 4.8% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 28.9B | ↓ 5.38% |
Net Income | 4.8B | ↑ 3.41% |
Net Profit Margin | 16.56% | ↑ 1.4% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 30.1B | ↑ 4.16% |
Net Income | 3.6B | ↓ 24.7% |
Net Profit Margin | 11.97% | ↓ 4.59% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 31.7B | ↑ 5.21% |
Net Income | 5.0B | ↑ 39.74% |
Net Profit Margin | 15.9% | ↑ 3.93% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.2B | ↓ 1.45% |
Net Income | 3.8B | ↓ 25.42% |
Net Profit Margin | 12.03% | ↓ 3.87% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 7.6B | ↑ 2.9% |
Net Income | 427.0M | ↓ 54.04% |
Net Profit Margin | 5.63% | ↓ 6.97% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.7B | ↑ 1.87% |
Net Income | 1.2B | ↑ 186.18% |
Net Profit Margin | 15.81% | ↑ 10.18% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.5B | ↑ 10.57% |
Net Income | 1.2B | ↓ 3.52% |
Net Profit Margin | 13.8% | ↓ 2.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.7B | ↓ 9.85% |
Net Income | 791.0M | ↓ 32.91% |
Net Profit Margin | 10.27% | ↓ 3.53% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.0B | ↑ 3.66% |
Net Income | 909.0M | ↑ 14.92% |
Net Profit Margin | 11.39% | ↑ 1.12% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.1B | ↑ 1.32% |
Net Income | 1.3B | ↑ 45.43% |
Net Profit Margin | 16.34% | ↑ 4.95% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 91.4B | ↓ 8.44% |
Total Liabilities | 40.6B | ↓ 17.87% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 89.7B | ↓ 1.86% |
Total Liabilities | 39.5B | ↓ 2.68% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 90.7B | ↑ 1.11% |
Total Liabilities | 39.8B | ↑ 0.85% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 93.1B | ↑ 2.64% |
Total Liabilities | 41.5B | ↑ 4.18% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 91.0B | ↓ 2.26% |
Total Liabilities | 38.3B | ↓ 7.77% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 90.9B | ↓ 0.04% |
Total Liabilities | 39.3B | ↑ 2.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 93.2B | ↑ 3.7% |
Total Liabilities | 41.2B | ↑ 11.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 94.1B | ↑ 0.96% |
Total Liabilities | 42.5B | ↑ 3.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 90.9B | ↓ 3.38% |
Total Liabilities | 39.3B | ↓ 7.6% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 90.8B | ↓ 0.19% |
Total Liabilities | 39.4B | ↑ 0.32% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 90.1B | ↓ 0.76% |
Total Liabilities | 38.4B | ↓ 2.46% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 90.8B | ↑ 0.83% |
Total Liabilities | 38.8B | ↑ 1.04% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.7B | ↓ 31.92% |
Investing Cash Flow | 5.9B | ↓ 472.88% |
Financing Cash Flow | -12.0B | ↑ 264.12% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 7.0B | ↑ 49.59% |
Investing Cash Flow | -774.0M | ↓ 113.21% |
Financing Cash Flow | -5.4B | ↓ 54.57% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 7.2B | ↑ 3.24% |
Investing Cash Flow | -3.2B | ↑ 313.82% |
Financing Cash Flow | -4.2B | ↓ 22.7% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.2B | ↓ 13.74% |
Investing Cash Flow | -2.9B | ↓ 10.52% |
Financing Cash Flow | -4.1B | ↓ 1.48% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 7.3B | ↑ 17.72% |
Investing Cash Flow | -1.7B | ↓ 42.11% |
Financing Cash Flow | -5.3B | ↑ 29.01% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.0B | ↓ 17.79% |
Investing Cash Flow | -3.5B | ↑ 110.55% |
Financing Cash Flow | -5.0B | ↓ 7.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 922.0M | ↓ 14.87% |
Investing Cash Flow | -1.1B | ↓ 27.7% |
Financing Cash Flow | 3.0B | ↓ 417.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↑ 70.72% |
Investing Cash Flow | -3.0B | ↑ 163.35% |
Financing Cash Flow | -2.1B | ↓ 170.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.5B | ↑ 56.29% |
Investing Cash Flow | -475.0M | ↓ 84.26% |
Financing Cash Flow | -4.9B | ↑ 129.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 875.0M | ↓ 64.43% |
Investing Cash Flow | -539.0M | ↑ 13.47% |
Financing Cash Flow | -501.0M | ↓ 89.75% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 661.0M | ↓ 24.46% |
Investing Cash Flow | -424.0M | ↓ 21.34% |
Financing Cash Flow | -90.0M | ↓ 82.04% |
Sell
Neutral
Buy
Medtronic Plc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Medtronic Plc | -1.47% | 11.26% | -9.42% | -35.83% | -9.38% |
Stryker Corporation | -6.09% | 18.64% | 13.94% | 29.24% | 71.95% |
Boston Scientific Corp. | 6.06% | 37.95% | 37.14% | 69.26% | 94.94% |
Edwards Lifesciences Corp. | -7.68% | 27.05% | -4.24% | -7.08% | 39.76% |
Abbott Laboratories | -4.18% | 11.47% | -4.51% | -10.85% | 33.93% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Medtronic Plc | 25.52 | 25.52 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Stryker Corporation | 40.83 | 40.83 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 68.14 | 68.14 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 37.58 | 37.58 | 5.19 | 2.75 | 0.21 | 0.12 | NA | 11.83 |
Abbott Laboratories | 33.3 | 33.3 | 5.99 | 4.6 | 0.15 | 0.06 | 0.02 | 22.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Medtronic Plc | Buy | $106.7B | -9.38% | 25.52 | 13.0% |
Stryker Corporation | Buy | $128.2B | 71.95% | 40.83 | 15.44% |
Boston Scientific Corp. | Buy | $107.2B | 94.94% | 68.14 | 11.18% |
Edwards Lifesciences Corp. | Buy | $52.0B | 39.76% | 37.58 | 23.01% |
Abbott Laboratories | Buy | $185.5B | 33.93% | 33.3 | 13.96% |
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Massachusetts Financial Services Company
Capital Research Global Investors
Geode Capital Management, LLC
In the quarter ending March,2024. Medtronic Plc has declared dividend of $0.69
Read MoreMedtronic plc is an American medical device company. The companys operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015.
Organization | Medtronic Plc |
Employees | 95000 |
CEO | Mr. Geoffrey Straub Martha |
Industry | Health Technology |